Medical and Pharmaceutical University of Manitoba researchers develop dual-mode breast cancer imaging system The system uses wave imaging to look inside breast tissue Joseph Morton6 days ago
AI and Autonomy AI-designed drugs near human trials as AlphaFold enters clinical phase Isomorphic Labs launched in 2021 as a unit of Alphabet Inc Joseph MortonApril 29, 2026
Medical and Pharmaceutical Researchers probe diet link as lung cancer rises in young non-smokers Scientists are investigating environmental, genetic, and lifestyle factors that could explain this shift Joseph MortonApril 22, 2026
Medical and Pharmaceutical Cancer remains Canada’s top killer as 2026 cases exceed 254,000 Age-standardized death rates are projected to decline overall Joseph MortonApril 17, 2026
AI and Autonomy Artificial intelligence reshapes cancer diagnosis from detection to prediction Developers have expanded AI applications into broader diagnostic tasks Joseph MortonApril 14, 2026
Health & Wellness Mayo Clinic study shows robotic tech improves early lung cancer diagnosis The system also integrates endobronchial ultrasound to examine nearby lymph nodes Joseph MortonApril 8, 2026
AI and Autonomy Tempus AI, Daiichi Sankyo team up to boost cancer drug trials with AI The companies plan to build proof-of-concept models that predict how patients will respond to treatment Joseph MortonMarch 27, 2026
Medical and Pharmaceutical FDA clears Median Technologies lung-nodule risk assessment software The Median system reported 93.3 per cent sensitivity and 92.4 per cent specificity when identifying malignant lung nodules Joseph MortonMarch 16, 2026
Medical and Pharmaceutical bioAffinity launches 2,000-patient study for noninvasive lung cancer test The test analyzes sputum samples using flow cytometry to identify cancer-related cellular changes Joseph MortonMarch 11, 2026
Medical and Pharmaceutical Tango Therapeutics rallies after oncology drug collaboration with Erasca Researchers think combining both drugs could create stronger and longer-lasting tumor responses Joseph MortonMarch 5, 2026